Results of Growth Hormone Treatment of Girls with Turner’s Syndrome in Slovakia
Authors:
Z. Šimeková 1; S. Bieliková 2; A. Gondová 3; Ľ. Košťálová 4; B. Milošovičová 5; Ž. Mišíková 4; M. Pašková 6; Z. Pribilincová 4; V. Šandriková 7
Authors‘ workplace:
Detské oddelenie NsP, Žilina1 primárka MUDr. D. SalátováDetská klinika NsP F. D. Roosevelta, Banská Bystrica2prednosta prof. MUDr. S. Dluholucký, CSc. I. detská klinika DFNsP a LFUK, Bratislava3 prednostka doc. MUDr. M. Benedeková, PhD. II. detská klinika
7
Published in:
Čes-slov Pediat 2003; (5): 262-264.
Category:
Overview
The main features of Turner’s syndrom (TS) are short stature and ovarian failure. Although the majority ofgirls with TS are not growth hormone deficient, growth hormone therapy is effective in improving their final height.The present paper report the results of a Slovak retrospective study of growth hormone therapy of 55 girls withTS who reached their final height. The mean age at the start of growth hormone treatment was 12.4 ± 2.1 years,the mean height SDS -3.4 ± 1.0, the mean duration of treatment 4.1 ± 1.4 years. The final height of the girls was153 ± 5.4 cm. The benefit resulting from growth - promoting therapy (final height - predicted adult height) is 7.1cm.Better results can be obtained with an earlier start of therapy, normalising height in childhood and inducingpuberty at an appropriate age.
Key words:
Turner syndrome, growth hormone therapy, final height
Labels
Neonatology Paediatrics General practitioner for children and adolescentsArticle was published in
Czech-Slovak Pediatrics
2003 Issue 5
Most read in this issue
- Septo-optic Dysplasia: Morphological, Ophthalmologic and Endocrine Findings in 11 Patients
- Biliary Atresia - Incidence and Therapeutic Results in Czech Republic
- Anti-Saccharomyces Cerevisiae Antibodies (ASCA) and Antineutrophil Cytoplasmic Antibodies(ANCA) in Children and Adolescents with Inflammatory Bowel Diseases
- Treatment of Chronic Renal Failure in Neonates, Infants and Toddlers